Arrowhead Pharmaceuticals (ARWR) Earnings Date, Estimates & Call Transcripts → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free ARWR Stock Alerts $21.81 -1.48 (-6.35%) (As of 11:11 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 7EstimatedActual EPS (Feb. 6) -$1.24 Missed By -$0.46 Consensus EPS (Feb. 6) -$0.78 Read Call TranscriptListen to Call Get Arrowhead Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for ARWR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueARWR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ARWR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. Arrowhead Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243($1.00)($0.29)($0.62) Q2 20244($1.17)($0.24)($0.59) Q3 20244($1.20)($0.24)($0.70) Q4 20244($1.33)$0.31($0.60) FY 202415($4.70)($0.46) ($2.50)ARWR Earnings Date and InformationArrowhead Pharmaceuticals last released its quarterly earnings data on February 6th, 2024. The biotechnology company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.46. The company had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. Its revenue was down 94.3% compared to the same quarter last year. Arrowhead Pharmaceuticals has generated ($2.78) earnings per share over the last year (($2.78) diluted earnings per share). Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.53) per share. Arrowhead Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off prior year's report dates.Read More Arrowhead Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/7/2024Estimated)------- 2/6/2024Q1 2024($0.78)($1.24)($0.46)($1.24)$35.60 million$3.55 million 11/29/2023Q4 2023($0.70)($1.03)($0.33)($1.03)$38.87 million$16.10 million8/7/2023Q3 2023($0.58)($0.96)($0.38)($0.96)$45.42 million$15.83 million 5/2/2023Q2 2023($0.65)$0.45+$1.10$0.45$45.48 million$146.27 million 2/6/2023Q4 2022$1.14($0.39)($1.53)($0.39)$162.52 million$62.55 million 11/28/2022Q4 2022($0.57)($0.81)($0.24)($0.81)$107.60 million$31.58 million Get the Latest News and Ratings for ARWR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q3 2022($0.45)($0.68)($0.23)($0.68)$52.61 million$32.41 million 5/10/2022Q2 2022$0.39$0.41+$0.02$0.41$122.15 million$151.80 million 2/2/2022Q1 2022($0.22)($0.60)($0.38)($0.60)$67.30 million$27.44 million 11/22/2021Q3 2021$0.04($0.61)($0.65)($0.61)$79.31 million$38.28 million 8/4/2021Q2 2021($0.08)($0.29)($0.21)($0.29)$50.20 million$45.89 million 5/3/2021Q1 2021($0.09)($0.26)($0.17)($0.26)$39.42 million$32.81 million Arrowhead Pharmaceuticals Earnings - Frequently Asked Questions When is Arrowhead Pharmaceuticals's earnings date? Arrowhead Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off last year's report dates. Learn more on ARWR's earnings history. Did Arrowhead Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) missed the analysts' consensus estimate of ($0.78) by $0.46 with a reported earnings per share (EPS) of ($1.24). Learn more on analysts' earnings estimate vs. ARWR's actual earnings. How can I listen to Arrowhead Pharmaceuticals's earnings conference call? The conference call for Arrowhead Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Arrowhead Pharmaceuticals's conference call transcript? The conference call transcript for Arrowhead Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Arrowhead Pharmaceuticals generate each year? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded annual revenue of $240.74 million. How much profit does Arrowhead Pharmaceuticals generate each year? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$205.27 million. ARWR has generated -$2.78 earnings per share over the last four quarters. What is Arrowhead Pharmaceuticals's EPS forecast for next year? Arrowhead Pharmaceuticals's earnings are expected to grow from ($2.70) per share to ($2.53) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ACAD Earnings Results IDYA Earnings Results MLTX Earnings Results FOLD Earnings Results XENE Earnings Results MOR Earnings Results INDV Earnings Results BHC Earnings Results JANX Earnings Results AXSM Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:ARWR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.